ABSTRACT
Background: Type 2 Diabetes Mellitus (T2DM) forms a direct link with obesity because it boosts both insulin resistance and damage to glucose metabolism. Treatment methods that existed before generally help control blood sugar but they do not provide stable results or proper weight control. Novel therapeutic approaches now aim to address both hyperglycemia along with obesity treatment to enhance patient results in recent medical developments.
Aim: The research sought to assess how well innovative treatments function and whether they are safe for Type 2 Diabetes Mellitus patients who are obese.
Methods: The research took place in Ayub Medical Hospital Abbottabad where 100 patients having T2DM and obesity formed the study group. The research period lasted from February 2024 until January 2025. Standard anti-diabetic treatment was present in Group A while Group B received GLP-1 receptor agonist and SGLT2 inhibitor combined therapy with lifestyle change education. Research investigators measured HbA1c as well as body weight and lipid profiles in patients both at the start of the study and twelve months later.
Results: Individuals within Group B achieved lower HbA1c numbers statistically (1.5% mean drop; p < .01) than individuals in Group A with a 0.7% mean drop. The participants in Group B lost more weight on average (6.4 kg versus 2.1 kg difference, p less than 0.01) than Group A until the end of the study period. There were no major negative effects observed and the treatment compliance rate proved higher among participants in the intervention group.
Conclusion: T2DM obese patients achieved superior glycemic management with weight loss when GLP-1 receptor agonists and SGLT2 inhibitors were used with lifestyle modification treatment. The research findings recommend the routine clinical adoption of these treatment therapies because they enhance patient disease management outcomes over time.
Keywords: Type 2 Diabetes Mellitus, Obesity, GLP-1 receptor agonists, SGLT2 inhibitors, Innovative treatment, Weight loss, Glycemic control.